OSAKA, Japan, February 24, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of April 1, 2021.
1. Corporate Reorganization (see attached organization chart)
(1) Reorganization of the Global Development Division
The Regulatory Affairs Supervisor will be progressively dissolved, and the affiliated organization will be directly under the Global Development Division.
(2) New establishment of the Vaccine Business Department
The Vaccine Business Department will be newly established under the Integrated Disease Care Division as an organization to promptly launch the vaccine business and prepare for the supply and distribution of vaccines.
2. Personnel Reassignment (Effective; April 1, 2021)
New Position |
Name |
Present Position |
Integrated Disease Care Division |
||
Vice president, Vaccine Business Department |
Norio Tamura |
Vice president, Regulatory Affairs Supervisor |
UMN Pharma Inc. |
||
Chairman |
Fumihisa Nakata |
President |
President |
Kazufumi Katayama |
UMN Pharma Inc. |